Investor Newsletter

Issue 07 2023

MicroPort®

MicroPort® MedBot™ DFVision™ 3D Electronic Laparoscope has obtained CE certification from the European Union



On June 19th, Shanghai Microport MedBot (Group) Co., Ltd. (hereinafter referred to as "MicroPort® MedBot™") successfully obtained CE certification from the European Union for its DFVision™ 3D Electronic Laparoscope (hereinafter referred to as "DFVision™"). With this achievement, DFVision™ becomes the first Chinese-developed 3D electronic laparoscope that has obtained both NMPA approval and CE certification in the European Union.

The certification process completed by DFVision™ is in accordance with the European Medical Device Regulation (Regulation [EU] 2017/745, referred to as MDR). MDR is a new regulation in the European Union for the medical device field. Compared to the previous Medical Device Directive (MDD), MDR focuses more on the device's clinical performance, better traceability of medical devices, and higher patient transparency. It imposes stricter requirements for market access of medical devices in the European Union and strengthens the requirements for manufacturers, importers, distributors, and notified bodies.

Mr. Liu Yu, Executive Vice President and Chief Commercial Officer of MicroPort® MedBot™, said, "Compared to traditional laparoscopy, DFVision™ is closer to and meets the surgical needs of doctors. After obtaining NMPA approval, obtaining CE certification from the European Union reaffirms the product's safety. In the future, MicroPort® MedBot™ will serve the medical community through clinical applications, allowing domestically advanced medical devices to maximize their value in clinical transformation and fulfill the initial mission of 'Make Surgery Easier, Safer and Less Invasive.'"



NDR Medical Technology, a Portfolio Company of MicroPort® MedBot™, Wins FDA 510(k) Clearance for its ANT-X™ Automatic Robotic

Recently, NDR Medical Technology Private Limited (hereinafter referred to as "NDR"), a portfolio company of Shanghai Microport MedBot (Group) Co., Ltd. (hereinafter referred to as "MicroPort® MedBot™"), has announced that its automated robotic device, Auto Needle Targeting system (hereinafter referred to as "ANT-X™"), has been granted FDA 510(k) clearance by the U.S. Food and Drug Administration (FDA). This clearance makes ANT-X™ the world's first FDA-approved C-arm guided Percutaneous Nephrolithotomy (PCNL) robotic device. Prior to that, ANT-X™ received the CE mark in 2020.

Mr. Liu Yu, Executive Vice President and Chief Commercial Officer of MicroPort® MedBot™, said, "With the development of technology, surgical robots have higher precision, consistency, and manipulability. Compared to traditional minimally invasive surgery, they can effectively reduce the burden on clinicians, improve the success rate of surgery, reduce the size of surgical incisions, and shorten the patient's postoperative recovery period. We hope that our surgical robotic products, such as Toumai™, SkyWalker™, Mona Lisa, R-ONE™, ANT-X™, and others, can be increasingly applied in clinical practice in the current context of continuously increasing demand for high-quality medical resources to solidify their value, benefit patients worldwide, and make surgeries easier all over the world."

MicroPort

MicroPort® Urocare three products have been approved by CE(MDR)

Recently, MicroPort® Urocare (Jiaxing) Medical Technology Co., Ltd. (hereinafter referred to as "MicroPort® Urocare") successfully completed the certification process of the European Medical Device Regulation MDR (2017/745) for its Disposable Urinary Guidewire, Nitinol Stone Extractor, and Stone Entrapment and Extraction Device.

The CE approval for these products indicates that international medical device regulatory authorities have recognized their effectiveness and safety. MicroPort® Urocare will continue to focus on innovative research and development, providing high-quality and affordable medical solutions for more patients worldwide.



MicroPort

Investor Newsletter

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
First Vice President of Board Secretary and Legal Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com